Browse by Audience
Skip to content
Papers of the Week
Improvements in disease activity partially mediate the effect of tofacitinib treatment on generic and disease-specific health-related quality of life in patients with ulcerative colitis: data from the OCTAVE program.
Abstract
Patients with ulcerative colitis (UC) often report impaired health-related quality of life (HRQoL). Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of UC. In addition to previous demonstrations of improved clinical measures (e.g., Mayo score), tofacitinib has been shown to improve HRQoL in patients with UC. This analysis explored the interrelationships among tofacitinib treatment, HRQoL, and disease activity (measured using Mayo subscores) using mediation modeling.